B 9430

a bradykinin B1/B2 receptor antagonist

Also Known As:

Arg(Hyp(3),Igl(5),Igl(7),Oic(8))BK; B-9430; arginyl(4-hydroxyprolyl(3)-(2-indanyl)glycyl(5,7)-octahydroindole-2-carboxylic acid(8))bradykinin

Networked: 3 relevant articles (0 outcomes, 1 trials/studies)

1.	Bawolak, Marie-Thérèse: 1 article (04/2012)
2.	Charest-Morin, Xavier: 1 article (04/2012)
3.	Gera, Lajos: 1 article (04/2012)
4.	Marceau, François: 1 article (04/2012)
5.	Roy, Caroline: 1 article (04/2012)
6.	Green, Mark R: 1 article (02/2002)
7.	Grethlein, Sara J: 1 article (02/2002)
8.	Herndon, James E: 1 article (02/2002)
9.	Lynch, Thomas J: 1 article (02/2002)
10.	Lyss, Alan P: 1 article (02/2002)

1.	Neoplasms (Cancer) 02/01/2002 - "Cancer and Leukemia Group B 9430 was a randomized phase II study evaluating 4 treatment arms in 57 evaluable, previously untreated E-SCLC patients. "
2.	Leukemia 02/01/2002 - "Cancer and Leukemia Group B 9430 was a randomized phase II study evaluating 4 treatment arms in 57 evaluable, previously untreated E-SCLC patients. "
3.	Tics (Tic) 04/01/2012 - "Antagonists (B(1)R: B-10376: CF-ε-ACA-Lys-Lys-[Hyp(3), CpG(5), D-Tic(7), CpG(8)]des-Arg(9)-BK; B(2)R: B-10380: CF-ε-ACA-D-Arg-[Hyp(3), Igl(5), D-Igl(7), Oic(8)]-BK and fluorescein-5-thiocarbamoyl (FTC)-B-9430) label the plasma membrane of cells expressing the cognate receptors. "
4.	Ischemia 01/01/2000 - "Animals with treatment received the bradykinin B1/B2 receptor antagonist B 9430 before (i.v.), during, and after ischemia (s.c.) until the end of the experiment. "
5.	Brain Ischemia (Cerebral Ischemia) 01/01/2000 - "The influence of the bradykinin B1/B2 antagonist B 9430 on the cerebral microcirculation following global cerebral ischemia was investigated in a closed cranial window preparation in Mongolian gerbils by intravital fluorescence microscopy. " 01/01/2000 - "Influence of the bradykinin B1/B2-receptor-antagonist B 9430 on the cerebral microcirculation and outcome of gerbils from global cerebral ischemia."